Apolipoprotein E: Far more than a lipid transport protein

Annual Review of Genomics and Human Genetics

Volumn 1, Issue 2000, 2000, Pages 507-537

  Mahley, Robert W ^a   Rall Jr , Stanley C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Coronary disease; Genetic polymorphism; Immunology; Infectious disease

Indexed keywords

APOLIPOPROTEIN E; ISOPROTEIN; LIPOPROTEIN;

ACTIVE TRANSPORT; ALLELE; ANIMAL; ARTERIOSCLEROSIS; CHEMICAL STRUCTURE; CHEMISTRY; COMMUNICABLE DISEASE; FEMALE; GENETIC POLYMORPHISM; GENETICS; HEART DISEASE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 3; IMMUNITY; LIPID METABOLISM; MALE; METABOLISM; NEUROBIOLOGY; PHENOTYPE; REPRODUCTION; REVIEW; RISK FACTOR;

ALLELES; ANIMALS; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; BIOLOGICAL TRANSPORT, ACTIVE; COMMUNICABLE DISEASES; FEMALE; HEART DISEASES; HUMANS; HYPERLIPOPROTEINEMIA TYPE III; IMMUNITY; LIPID METABOLISM; LIPOPROTEINS; MALE; MODELS, MOLECULAR; NEUROBIOLOGY; PHENOTYPE; POLYMORPHISM, GENETIC; PROTEIN ISOFORMS; REPRODUCTION; RISK FACTORS;

EID: 0034575124     PISSN: 15278204     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.genom.1.1.507     Document Type: Article

References (117)

1. Aggerbeck LP, Wetterau JR, Weisgraber KH, Wu C-SC, Lindgren FT. 1988. Human apolipoprotein E3 in aqueous solution. II. Properties of the amino-and carboxyl-terminal domains. J. Biol. Chem. 263:6249-58
2. Arai T, Rinninger F, Varban L, Fairchild-Huntress V, Liang C-P, et al. 1999. Decreased selective uptake of high density lipoprotein cholesteryl esters in apolipoprotein E knock-out mice. Proc. Natl. Acad. Sci. USA 96:12050-55
3. Bellosta S, Mahley RW, Sanan DA, Murata J, Newland DL, et al. 1995. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J. Clin. Invest. 96:2170-79
4. Bellosta S, Nathan BP, Orth M, Dong L-M, Mahley RW, Pitas RE. 1995. Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neunte outgrowth. J. Biol. Chem. 270:27063-71
5. Bergeron N, Havel RJ. 1996. Prolonged postprandial responses of lipids and apolipoproteins in triglyceride-rich lipoproteins of individuals expressing an apolipoprotein ε4 allele. J. Clin. Invest. 97:65-72
6. Boerwinkle E, Brown SA, Rohrbach K, Gotto AM Jr, Patsch W. 1991. Role of apolipoprotein E and B gene variation in determining response of lipid, lipoprotein, and apolipoprotein levels to increased dietary cholesterol. Am. J. Hum. Genet. 49:1145-54
7. Brown MS, Goldstein JL. 1983. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu. Rev. Biochem. 52:223-61
8. Browning PJ, Roberts DD, Zabrenetzky V, Bryant J, Kaplan M, et al. 1994. Apolipoprotein E (apoE), a novel heparin-binding protein inhibits the development of Kaposi's sarcoma-like lesions in BALB/c nu/nu mice. J. Exp. Med. 180:1949-54
9. -/- mice: isoform-specific effects on neurodegeneration. J. Neurosci. 19:4867-80
10. Cardin AD, Bowlin TL, Krstenansky JL. 1988. Inhibition of lymphocyte proliferation by synthetic peptides homologous to human plasma apolipoproteins B and E. Biochem. Biophys. Res. Commun. 154:741-45
11. Caselli RJ, Graff-Radford NR, Reiman EM, Weaver A, Osborne D, et al. 1999. Preclinical memory decline in cognitively normal apolipoprotein E-ε4 homozygotes. Neurology 53:201-7
12. Cooper AD. 1997. Hepatic uptake of chylomicron remnants. J. Lipid Res. 38:2173-92
13. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, et al. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-23
14. Curtiss LK, Edgington TS. 1976. Regulatory serum lipoproteins: regulation of lymphocyte stimulation by a species of low density lipoprotein. J. Immunol. 116:1452-58
15. Cuthbert JA, Lipsky PE. 1984. Modulation of human lymphocyte responses by low density lipoproteins (LDL): enhancement but not immunosuppression is mediated by LDL receptors. Proc. Natl. Acad. Sci. USA 81:4539-43
16. Cuthbert JA, Lipsky PE. 1984. Immunoregulation by low density lipoproteins in man. Inhibition of mitogen-induced T lymphocyte proliferation by interference with transferrin metabolism. J. Clin. Invest. 73:992-1003
17. Dallongeville J, Lussier-Cacan S, Davignon J. 1992. Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J. Lipid Res. 33:447-54
18. D'Arcangelo G, Homayouni R, Keshvara L, Rice DS, Sheldon M, Curran T. 1999. Reelin is a ligand for lipoprotein receptors. Neuron 24:471-79
19. Davignon J, Gregg RE, Sing CF. 1988. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8:1-21
20. de Bont N, Netea MG, Demacker PNM, Verschueren I, Kullberg BJ, et al. 1999. Apolipoprotein E knock-out mice are highly susceptible to endotoxemia and Klebsiella pneumoniae infection. J. Lipid Res. 40:680-85
21. DeMattos RB, Curtiss LK, Williams DL. 1998. A minimally lipidated form of cell-derived apolipoprotein E exhibits isoform-specific stimulation of neunte outgrowth in the absence of exogenous lipids or lipoproteins. J. Biol. Chem. 273:4206-12
22. Dong L-M, Parkin S, Trakhanov SD, Rupp B, Simmons T, et al. 1996. Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia. Nat. Struct. Biol. 3:718-22
23. Dong L-M, Weisgraber KH. 1996. Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. J. Biol. Chem. 271:19053-57
24. Dong L-M, Wilson C, Wardell MR, Simmons T, Mahley RW, et al. 1994. Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J. Biol. Chem. 269:22358-65
25. Dyer CA, Smith RS, Curtiss LK. 1991. Only multimers of a synthetic peptide of human apolipoprotein E are biologically active. J. Biol. Chem. 266:15009-15
26. Fazio S, Babaev VR, Murray AB, Hasty AH, Carter KJ, et al. 1997. Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages. Proc. Natl. Acad. Sci. USA 94:4647-52
27. Fazio S, Sanan DA, Lee Y-L, Ji Z-S, Mahley RW, Rall SC Jr. 1994. Susceptibility to diet-induced atherosclerosis in transgenic mice expressing a dysfunctional human apolipoprotein E(Arg 112,Cys142). Arterioscler. Thromb. Vasc. Biol. 14:1873-79
28. Finch CE, Sapolsky RM. 1999. The evolution of Alzheimer disease, the reproductive schedule, and apoE isoforms. Neurobiol. Aging 20:407-28
29. Fredrickson DS, Levy RI, Lees RS. 1967. Fat transport in lipoproteins - an integrated approach to mechanisms and disorders. N. Engl. J. Med. 276:34-44, 94-103, 148-56, 215-25, 273-81
30. Gerdes LU, Gerdes C, Hansen PS, Klausen IC, Færgeman O. 1996. Are men carrying the apolipoprotein ε4 or ε2 allele less fertile than ε3ε3 genotypes? Hum. Genet. 98:239-42
31. Gerdes LU, Gerdes C, Hansen PS, Klausen IC, Færgeman O, Dyerberg J. 1996. The apolipoprotein E polymorphism in Greenland Inuit in its global perspective. Hum. Genet. 98:546-50
32. Gregg RE, Zech LA, Schaefer EJ, Stark D, Wilson D, Brewer HB Jr. 1986. Abnormal in vivo metabolism of apolipoprotein E4 in humans. J. Clin. Invest. 78:815-21
33. Han S-H, Einstein G, Weisgraber KH, Strittmatter WJ, Saunders AM, et al. 1994. Apolipoprotein E is localized to the cytoplasm of human cortical neurons: a light and electron microscopic study. J. Neuropathol. Exp. Neurol. 53:535-44
34. Hanlon CS, Rubinsztein DC. 1995. Arginine residues at codons 112 and 158 in the apolipoprotein E gene correspond to the ancestral state in humans. Atherosclerosis 112:85-90
35. Harmony JAK, Akeson AL, McCarthy BM, Morris RE, Scupham DW, Grupp SA. 1986. Immunoregulation by plasma lipoproteins. In Biochemistry and Biology of Plasma Lipoproteins, ed. AM Scanu, AA Spector, pp. 403-52. New York: Marcel Dekker
36. Herz J. 1993. The LDL-receptor-related protein - portrait of a multifunctional receptor. Curr. Opin. Lipidol. 4:107-13
37. Herz J, Willnow TE. 1994. Functions of the LDL receptor gene family. Ann. NY Acad. Sci. 737:14-19
38. Hiesberger T, Trommsdorff M, Howell BW, Goffinet A, Mumby MC, et al. 1999. Direct binding of reelin to VLDL receptor and apoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation. Neuron 24:481-89
39. Holtzman DM, Pitas RE, Kilbridge J, Nathan B, Mahley RW, et al. 1995. Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neunte outgrowth in a central nervous system-derived neuronal cell line. Proc. Natl. Acad. Sci. USA 92:9480-84
40. Huang Y, Ji Z-S, Brecht WJ, Rall SC Jr, Taylor JM, Mahley RW. 1999. Overexpression of apolipoprotein E3 in transgenic rabbits causes combined hyperlipidemia by stimulating hepatic very low density lipoprotein (VLDL) production and impairing VLDL lipolysis. Arterioscler. Thromb. Vasc. Biol. 19:2952-59
41. Huang Y, Liu XQ, Rall SC Jr, Mahley RW. 1998. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins. J. Biol. Chem. 273:17483-90
42. Huang Y, Liu XQ, Rall SC Jr, Taylor JM, von Eckardstein A, et al. 1998. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. J. Biol. Chem. 273:26388-93
43. Huang Y, Rall SC Jr, Mahley RW. 1997. Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2. Arterioscler. Thromb. Vasc. Biol. 17:2817-24
44. Huang Y, Schwendner SW, Rall SC Jr, Sanan DA, Mahley RW. 1997. Apolipoprotein E2 transgenic rabbits: modulation of the type III hyperlipoproteinemic phenotype by estrogen and occurrence of spontaneous atherosclerosis. J. Biol. Chem. 272:22685-94
45. Huang Y, von Eckardstein A, Wu S, Maeda N, Assmann G. 1994. A plasma lipoprotein containing only apolipoprotein E and with y mobility on electrophoresis releases cholesterol from cells. Proc. Natl. Acad. Sci. USA 91:1834-38
46. + accumulation in mitogen-activated lymphocytes: role of membrane-bound plasma lipoproteins. Proc. Natl. Acad. Sci. USA 77:4764-68
47. Hui DY, Harmony JAK, Innerarity TL, Mahley RW. 1980. Immunoregulatory plasma lipoproteins. Role of apoprotein E and apoprotein B. J. Biol. Chem. 255:11775-81
48. Hyman BT, Gomez-Isla T, Briggs M, Chung H, Nichols S, et al. 1996. Apolipoprotein E and cognitive change in an elderly population. Ann. Neurol. 40:55-66
49. Innerarity TL, Weisgraber KH, Arnold KS, Rall SC Jr, Mahley RW. 1984. Normalization of receptor binding of apolipoprotein E2. Evidence for modulation of the binding site conformation. J. Biol. Chem. 259:7261-67
50. 1 phase. J. Biol. Chem. 273:20156-61
51. Itzhaki RF, Lin W-R, Shang D, Wilcock GK, Faragher B, Jamieson GA. 1997. Herpes simplex virus type 1 in brain and risk of Alzheimer's disease. Lancet 349:241-44
52. Ji Z-S, Pitas RE, Mahley RW. 1998. Differential cellular accumulation/retention of apolipoprotein E mediated by cell surface heparan sulfate proteoglycans. Apolipoproteins E3 and E2 greater than E4. J. Biol. Chem. 273:13452-60
53. Jong MC, Dahlmans VEH, van Gorp PJJ, Breuer ML, Mol MJTM, et al. 1996. Both lipolysis and hepatic uptake of VLDL are impaired in transgenic mice coexpressing human apolipoprotein E*3Leiden and human apolipoprotein Cl. Arterioscler. Thromb. Vasc. Biol. 16:934-40
54. Kelly ME, Clay MA, Mistry MJ, Hsieh-Li H-M, Harmony JAK. 1994. Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: production of interleukin 2 with reduced biological activity. Cell. Immunol. 159:124-39
55. Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, et al. 1995. LDL receptor-related protein, a multifunctional apoE receptor, binds secreted β-amyloid precursor protein and mediates its degradation. Cell 82:331-40
56. LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE. 1994. Isoformspecific binding of apolipoprotein to β-amyloid. J. Biol. Chem. 269:23403-6
57. LaDu MJ, Lukens JR, Reardon CA, Getz GS. 1997. Association of human, rat, and rabbit apolipoprotein E with β-amyloid. J. Neurosci. Res. 49:9-18
58. 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 372:92-94
59. Mahley RW. 1988. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240:622-30
60. Mahley RW. 1997. Apolipoprotein E: structure and function in lipid metabolism and neurobiology. In The Molecular and Genetic Basis of Neurological Disease, ed. RN Rosenberg, SB Prusiner, S Di-Mauro, RL Barchi, pp. 1037-49. Boston: Butterworth-Heinemann. 2nd ed.
61. Mahley RW, Huang Y. 1999. Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr. Opin. Lipidol. 10:207-17
62. Mahley RW, Huang Y, Rall SC Jr. 1999. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes. J. Lipid Res. 40:1933-49
63. Mahley RW, Innerarity TL. 1983. Lipoprotein receptors and cholesterol homeostasis. Biochim. Biophys. Acta 737:197-222
64. Mahley RW, Ji Z-S. 1999. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J. Lipid Res. 40:1-16
65. Mahley RW, Nathan BP, Bellosta S, Pitas RE. 1995. Apolipoprotein E: impact of cytoskeletal stability in neurons and the relationship to Alzheimer's disease. Curr. Opin. Lipidol. 6:86-91
66. Mahley RW, Rall SC Jr. 1995. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In The Metabolic and Molecular Bases of Inherited Disease, ed. CR Scriver, AL Beaudet, WS Sly, D Valle, pp. 1953-80. New York: McGraw-Hill. 7th ed.
67. Mahley RW, Weisgraber KH, Farese RV Jr. 1998. Disorders of lipid metabolism. In Williams Textbook of Endocrinology, ed. JD Wilson, DW Foster, HM Kronenberg, PR Larsen, pp. 1099-153. Philadelphia: Saunders. 9th ed.
68. Majack RA, Castle CK, Goodman LV, Weisgraber KH, Mahley RW, et al. 1988. Expression of apolipoprotein E by cultured vascular smooth muscle cells is controlled by growth state. J. Cell Biol. 107:1207-13
69. Martin I, Dubois M-C, Saermark T, Ruysschaert J-M. 1992. Apolipoprotein A-1 interacts with the N-terminal fusogenic domains of SIV (simian immunodeficiency virus) GP32 and HTV (human immunodeficiency virus) GP41 : implications in viral entry. Biochem. Biophys. Res. Commun. 186:95-101
70. Menzel H-J, Kladetzky R-G, Assmann G. 1983. Apolipoprotein E polymorphism and coronary artery disease. Arteriosclerosis 3:310-15
71. Miyata M, Smith JD. 1996. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and β-amyloid peptides. Nat. Genet. 14:55-61
72. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. 1994. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb. 14:133-40
73. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. 1994. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 264:850-52
74. Nathan BP, Chang K-C, Bellosta S, Brisch E, Ge N, et al. 1995. The inhibitory effect of apolipoprotein E4 on neunte outgrowth is associated with microtubule depolymerization. J. Biol Chem. 270:19791-99
75. Netea MG, Demacker PNM, Kullberg BJ, Boerman OC, Verschueren I, et al. 1996. Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections. J. Clin. Invest. 97:1366-72
76. Nicoll JAR, Roberts GW, Graham DI. 1996. Amyloid β-protein, APOE genotype and head injury. Ann. NY Acad. Sci. 777:271-75
77. Owens RJ, Anantharamaiah GM, Kahlon JB, Srinivas RV, Compans RW, Segrest JP. 1990. Apolipoprotein A-I and its amphipathic helix peptide analogues inhibit human immunodeficiency virus-induced syncytium formation. J. Clin. Invest. 86:1142-50
78. Raber J, Wong D, Buttini M, Orth M, Bellosta S, et al. 1998. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proc. Natl. Acad. Sci. USA 95:10914-19
79. Rall SC Jr, Mahley RW. 1992. The role of apolipoprotein E genetic variants in lipoprotein disorders. J. Intern. Med. 231:653-59
80. Rall SC Jr, Weisgraber KH, Mahley RW. 1982. Human apolipoprotein E. The complete amino acid sequence. J. Biol. Chem. 257:4171-78
81. Reddick RL, Zhang SH, Maeda N. 1994. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler. Thromb. 14:141-47
82. Rensen PCN, van Berkel TJC. 1996. Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions in vitro and in vivo. J. Biol. Chem. 271:14791-99
83. Roselaar SE, Daugherty A. 1998. Apolipoprotein E-deficient mice have impaired innate immune responses to Listeria monocytogenes in vivo. J. Lipid Res. 39:1740-43
84. Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, et al. 1994. Apolipoprotein E associates with βamyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J. Clin. Invest. 94:860-69
85. Schneider WJ, Kovanen PT, Brown MS, Goldstein JL, Utermann G, et al. 1981. Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows. J. Clin. Invest. 68:1075-85
86. Shakibaei M, Frevert U. 1996. Dual interaction of the malaria circumsporozoite protein with the low density lipoprotein receptor-related protein (LRP) and heparan sulfate proteoglycans. J. Exp. Med. 184:1699-711
87. Sheng H, Laskowitz DT, Bennett E, Schmechel DE, Bart RD, et al. 1998. Apolipoprotein E isoform-specific differences in outcome from focal ischemia in transgenic mice. J. Cereb. Blood Flow Metab. 18:361-66
88. Sing CF, Davignon J. 1985. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am. J. Hum. Genet. 37:268-85
89. Sinnis P, Willnow TE, Briones MRS, Herz J, Nussenzweig V. 1996. Remnant lipoproteins inhibit malaria sporozoite invasion of hepatocytes. J. Exp. Med. 184:945-54
90. Slooter AJC, Tang M-X, van Duijn CM, Stern Y, Ott A, et al. 1997. Apolipoprotein E ε4 and the risk of dementia with stroke. A population-based investigation. JAMA 277:818-21
91. Small GW, Chen ST, Komo S, Ercoli L, Bookheimer S, et al. 1999. Memory self-appraisal in middle-aged and older adults with the apolipoprotein E-4 allele. Am. J. Psychiatry 156:1035-38
92. Stengård JH, Zerba KE, Pekkanen J, Ehnholm C, Nissinen A, Sing CF 1995. Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation 91:265-69
93. Strittmatter WJ, Saunders AM, Goedert M, Weisgraber KH, Dong L-M, et al. 1994. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc. Natl. Acad. Sci. USA 91:11183-86
94. Strittmatter WJ, Weisgraber KH, Huang DY, Dong L-M, Salvesen GS, et al. 1993. Binding of human apolipoprotein E to synthetic amyloid βpeptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 90:8098-102
95. Sun YL, Wu S, Bu GJ, Onifade MK, Patel SN, et al. 1998. Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. J. Neurosci. 18:3261-72
96. Trommsdorff M, Borg J-P, Margolis B, Herz J. 1998. Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein. J. Biol. Chem. 273:33556-60
97. Utermann G. 1985. Genetic polymorphism of apolipoprotein E - impact on plasma lipoprotein metabolism. In Diabetes, Obesity and Hyperlipidemias - III, ed. G Crepaldi, A Tiengo, G Baggio, pp. 1-28. Amsterdam: Elsevier Science
98. Utermann G, Hees M, Steimnetz A. 1977. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Nature 269:604-7
99. Utermann G, Kindermann I, Kaffarnik H, Steinmetz A. 1984. Apolipoprotein E phenotypes and hyperlipidemia. Hum. Genet. 65:232-36
100. Utermann G, Langenbeck U, Beisiegel U, Weber W. 1980. Genetics of the apolipoprotein E system in man. Am. J. Hum. Genet. 32:339-47
101. Utermann G, Steinmetz A, Weber W. 1982. Genetic control of human apolipoprotein E polymorphism: comparison of one-and two-dimensional techniques of isoprotein analysis. Hum. Genet. 60:344-51
102. van Dijk KW, van Vlijmen BJM, van't Hof HB, van der Zee A, Santamarina-Fojo S, et al. 1999. In LDL receptor-deficient mice, catabolism of remnant lipoproteins requires a high level of apoE but is inhibited by excess apoE. J. Lipid Res. 40:336-44
103. van Vlijmen BJM, van den Maagdenberg AMJM, Gijbels MJJ, van der Boom H, HogenEsch H, et al. 1994. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J. Clin. Invest. 93:1403-10
104. Weintraub MS, Eisenberg S, Breslow JL. 1987. Dietary fat clearance in normal subjects is regulated by genetic variation of apolipoprotein E. J. Clin. Invest. 80:1571-77
105. Weisgraber KH. 1994. Apolipoprotein E: structure-function relationships. Adv. Protein Chem. 45:249-302
106. Weisgraber KH, Innerarity TL, Mahley RW. 1982. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J. Biol. Chem. 257:2518-21
107. Weisgraber KH, Mahley RW. 1996. Human apolipoprotein E: the Alzheimer's disease connection. FASEB J. 10:1485-94
108. Weisgraber KH, Pitas RE, Mahley RW. 1994. Lipoproteins, neurobiology, and Alzheimer's disease: structure and function of apolipoprotein E. Curr. Opin. Struct. Biol. 4:507-15
109. Wernette-Hammond ME, Lauer SJ, Corsini A, Walker D, Taylor JM, Rall SC Jr. 1989. Glycosylation of human apolipoprotein E. The carbohydrate attachment site is threonine 194. J. Biol. Chem. 264:9094-101
110. Wetterau JR, Aggerbeck LP, Rall SC Jr, Weisgraber KH. 1988. Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. J. Biol. Chem. 263:6240-48
111. Wilson C, Mau T, Weisgraber KH, Wardell MR, Mahley RW, Agard DA. 1994. Salt bridge relay triggers defective LDL receptor binding by a mutant apolipoprotein. Structure 2:713-18
112. Wilson C, Wardell MR, Weisgraber KH, Mahley RW, Agard DA. 1991. Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 252:1817-22
113. Wisniewski T, Castaño EM, Golabek A, Vogel T, Frangione B. 1994. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am. J. Pathol. 145:1030-35
114. Yankner BA, Duffy LK, Kirschner DA. 1990. Neurotrophic and neurotoxic effects of amyloid βprotein: reversal by tachykinin neuropeptides. Science 250:279-82
115. Zannis VI, Breslow JL. 1981. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and post-translational modification. Biochemistry 20:1033-41
116. Zannis VI, Breslow JL, Utermann G, Mahley RW, Weisgraber KH, et al. 1982. Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. J. Lipid Res. 23:911-14
117. Zannis VI, Just PW, Breslow JL. 1981. Human apolipoprotein E isoprotein subclasses are genetically determined. Am. J. Hum. Genet. 33:11-24